Giovanni Tosi

List of Publications by Year
in descending order

108 papers	4,572 citations	87723 38 h-index	110170 64 g-index
109 all docs	109 docs citations	109 times ranked	6239 citing authors

#	Article	IF	Citations
1	Delivering the power of nanomedicine to patients today. Journal of Controlled Release, 2020, 326, 164-171.	4.8	219
2	Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. Journal of Controlled Release, 2007, 122, 1-9.	4.8	217
3	Peptide-derivatized biodegradable nanoparticles able to cross the bloodâ€"brain barrier. Journal of Controlled Release, 2005, 108, 84-96.	4.8	202
4	Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opinion on Drug Delivery, 2008, 5, 155-174.	2.4	189
5	Application of metalâ€‰â€"â€‰organic frameworks. Polymer International, 2017, 66, 731-744.	1.6	163
6	Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges. Journal of Controlled Release, 2017, 245, 95-107.	4.8	156
7	AFM, ESEM, TEM, and CLSM in liposomal characterization: a comparative study. International Journal of Nanomedicine, 2011, 6, 557.	3.3	150
8	Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine: Nanotechnology, Biology, and Medicine, 2009, 5, 369-377.	1.7	133
9	Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates. International Journal of Pharmaceutics, 2017, 526, 413-424.	2.6	127
10	Nanoparticle transport across the blood brain barrier. Tissue Barriers, 2016, 4, e1153568.	1.6	121
11	Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier. Current Medicinal Chemistry, 2013, 20, 2212-2225.	1.2	113
12	Atomic force microscopy and photon correlation spectroscopy: Two techniques for rapid characterization of liposomes. European Journal of Pharmaceutical Sciences, 2005, 25, 81-89.	1.9	112
13	Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. Journal of Controlled Release, 2010, 145, 49-57.	4.8	110
14	Drug delivery across the bloodâ€"brain barrier: recent advances in the use of nanocarriers. Nanomedicine, 2020, 15, 205-214.	1.7	101
15	Protein corona and nanoparticles: how can we investigate on?. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2017, 9, e1467.	3.3	93
16	Cholesterolâ€loaded nanoparticles ameliorate synaptic and cognitive function in <scp>H</scp> untington's disease mice. EMBO Molecular Medicine, 2015, 7, 1547-1564.	3.3	84
17	Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier. Expert Opinion on Drug Delivery, 2020, 17, 23-32.	2.4	83
18	Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the bloodâ€"brain barrier. Nanomedicine, 2011, 6, 423-436.	1.7	80

#	Article	IF	Citations
19	Application of atomic force microscopy to characterize liposomes as drug and gene carriers. Talanta, 2007, 73, 12-22.	2.9	78
20	Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders. PLoS ONE, 2016, 11, e0156452.	1.1	72
21	Nanoparticulate drug carriers based on hybrid poly(d,l-lactide-co-glycolide)-dendron structures. Biomaterials, 2006, 27, 4635-4645.	5.7	68
22	PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. Biomaterials, 2010, 31, 3395-3403.	5.7	64
23	Reduced plaque size and inflammation in the APP23 mouse model for Alzheimerâ€™s disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery. Journal of Trace Elements in Medicine and Biology, 2018, 49, 210-221.	1.5	64
24	Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. Journal of Controlled Release, 2014, 174, 195-201.	4.8	63
25	PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting. Nanomedicine, 2015, 10, 1735-1750.	1.7	60
26	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimerâ€™s disease: from current to future challenges. Journal of Nanobiotechnology, 2021, 19, 122.	4.2	60
27	The â€œfateâ€•of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of bloodâ€"brain barrier crossing and trafficking into the central nervous system. Journal of Drug Delivery Science and Technology, 2016, 32, 66-76.	1.4	58
28	PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury. Molecular Neurobiology, 2015, 52, 899-912.	1.9	57
29	Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport. Journal of Controlled Release, 2014, 177, 96-107.	4.8	48
30	Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin. Expert Opinion on Drug Delivery, 2017, 14, 825-840.	2.4	47
31	Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles. International Journal of Molecular Sciences, 2019, 20, 2014.	1.8	47
32	Development of Novel Zn2+ Loaded Nanoparticles Designed for Cell-Type Targeted Drug Release in CNS Neurons: In Vitro Evidences. PLoS ONE, 2011, 6, e17851.	1.1	46
33	Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles. Pharmaceutics, 2015, 7, 74-89.	2.0	46
34	PLGA-PEG-ANG-2 Nanoparticles for Bloodâ€"Brain Barrier Crossing: Proof-of-Concept Study. Pharmaceutics, 2020, 12, 72.	2.0	46
35	NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences. Journal of Neural Transmission, 2011, 118, 145-153.	1.4	45
36	Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery?. Nanomedicine, 2012, 7, 365-382.	1.7	44

#	Article	IF	Citations
37	Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials, 2005, 26, 4189-4195.	5.7	42
38	Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy. Progress in Brain Research, 2019, 245, 57-88.	0.9	39
39	Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease. Journal of Controlled Release, 2021, 330, 587-598.	4.8	33
40	Applications of the ROS-Responsive Thioketal Linker for the Production of Smart Nanomedicines. Polymers, 2022, 14, 687.	2.0	33
41	Colloidal systems for CNS drug delivery. Progress in Brain Research, 2009, 180, 35-69.	0.9	32
42	Sialic acid as a potential approach for the protection and targeting of nanocarriers. Expert Opinion on Drug Delivery, 2011, 8, 921-937.	2.4	31
43	ROS-responsive â€œsmartâ€•polymeric conjugate: Synthesis, characterization and proof-of-concept study. International Journal of Pharmaceutics, 2019, 570, 118655.	2.6	31
44	PLA-microparticles formulated by means a thermoreversible gel able to modify protein encapsulation and release without being co-encapsulated. International Journal of Pharmaceutics, 2006, 323, 131-138.	2.6	30
45	Emerging Use of Nanotechnology in the Treatment of Neurological Disorders. Current Pharmaceutical Design, 2015, 21, 3111-3130.	0.9	28
46	Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders. International Review of Neurobiology, 2017, 137, 1-28.	0.9	27
47	Neurotrophic Factors and Neurodegenerative Diseases. International Review of Neurobiology, 2012, 102, 207-247.	0.9	26
48	Brain-targeted polymeric nanoparticles: <i>in vivo</i> evidence of different routes of administration in rodents. Nanomedicine, 2013, 8, 1373-1383.	1.7	26
49	Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain. International Journal of Pharmaceutics, 2018, 543, 300-310.	2.6	26
50	Collagen-based modified membranes for tissue engineering: Influence of type and molecular weight of GAGs on cell proliferation. International Journal of Pharmaceutics, 2009, 378, 108-115.	2.6	25
51	AFM phase imaging of soft-hydrated samples: A versatile tool to complete the chemical-physical study of liposomes. Journal of Liposome Research, 2009, 19, 59-67.	1.5	25
52	Chemico-physical investigation of tenofovir loaded polymeric nanoparticles. International Journal of Pharmaceutics, 2012, 436, 753-763.	2.6	25
53	Nuclear localization of cationic solid lipid nanoparticles containing Protamine as transfection promoter. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 384-393.	2.0	23
54	Nanoparticles as Bloodâ€“Brain Barrier Permeable CNS Targeted Drug Delivery Systems. Topics in Medicinal Chemistry, 2013, , 71-89.	0.4	22

#	Article	IF	Citations
55	Nanomedicine: the future for advancing medicine and neuroscience. Nanomedicine, 2012, 7, 1113-1116.	1.7	21
56	Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment. Frontiers in Pharmacology, 2020, 11, 574.	1.6	21
57	Poly (D,L-Lactide-co-Glycolide) Nanoparticles Loaded with Cerebrolysin Display Neuroprotective Activity in a Rat Model of Concussive Head Injury. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1475-1482.	0.8	21
58	Nanoparticle formulation may affect the stabilization of an antiischemic prodrug. International Journal of Pharmaceutics, 2006, 307, 103-113.	2.6	20
59	Use of Polylactide-Co-Glycolide-Nanoparticles for Lysosomal Delivery of a Therapeutic Enzyme in Glycogenosis Type II Fibroblasts. Journal of Nanoscience and Nanotechnology, 2015, 15, 2657-2666.	0.9	20
60	Novel peptide-conjugated nanomedicines for brain targeting: In vivo evidence. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102226.	1.7	20
61	Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'. Current Medicinal Chemistry, 2014, 21, 4169-4185.	1.2	20
62	Ketorolac Tromethamine Liposomes: Encapsulation and Release Studies. Journal of Liposome Research, 2005, 15, 175-185.	1.5	18
63	Detection of PLGA-based nanoparticles at a single-cell level by synchrotron radiation FTIR spectromicroscopy and correlation with X-ray fluorescence microscopy. International Journal of Nanomedicine, 2014, 9, 2791.	3.3	18
64	Nanomedicine Against Aβ Aggregation by β€“Sheet Breaker Peptide Delivery: In Vitro Evidence. Pharmaceutics, 2019, 11, 572.	2.0	18
65	Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release. International Journal of Pharmaceutics, 2014, 471, 349-357.	2.6	17
66	PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 99, 7-17.	2.0	17
67	Nerve Growth Factor Biodelivery: A Limiting Step in Moving Toward Extensive Clinical Application?. Frontiers in Neuroscience, 2021, 15, 695592.	1.4	17
68	Cidofovir-loaded liposomes: an intro-study using BCBL-1 cell line as a model for primary effusion lymphoma. European Journal of Pharmaceutical Sciences, 2010, 41, 254-264.	1.9	16
69	Brain targeting with polymeric nanoparticles: which administration route should we take?. Nanomedicine, 2013, 8, 1361-1363.	1.7	16
70	Apoferritin nanocage as drug reservoir: is it a reliable drug delivery system?. Expert Opinion on Drug Delivery, 2016, 13, 1341-1343.	2.4	16
71	Investigating Novel Syntheses of a Series of Unique Hybrid PLGA-Chitosan Polymers for Potential Therapeutic Delivery Applications. Polymers, 2020, 12, 823.	2.0	16
72	Nanomedicine and neurodegenerative disorders: so close yet so far. Expert Opinion on Drug Delivery, 2015, 12, 1041-1044.	2.4	15

#	Article	IF	Citations
73	Apoferritin nanocage as streptomycin drug reservoir: Technological optimization of a new drug delivery system. International Journal of Pharmaceutics, 2017, 518, 281-288.	2.6	14
74	Enzyme Stability in Nanoparticle Preparations Part 1: Bovine Serum Albumin Improves Enzyme Function. Molecules, 2020, 25, 4593.	1.7	14
75	Intact collagen and atelocollagen sponges: Characterization and ESEM observation. Materials Science and Engineering C, 2007, 27, 802-810.	3.8	13
76	Antioxidant activity and photostability assessment of trans-resveratrol acrylate microspheres. Pharmaceutical Development and Technology, 2019, 24, 222-234.	1.1	13
77	DOTAP/UDCA vesicles: novel approach in oligonucleotide delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2007, 3, 1-13.	1.7	12
78	Biodegradable device applied in flatfoot surgery: Comparative studies between clinical and technological aspects of removed screws. Materials Science and Engineering C, 2013, 33, 1773-1782.	3.8	12
79	Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo. CNS and Neurological Disorders - Drug Targets, 2015, 14, 1041-1053.	0.8	12
80	AFM and TEM characterization of siRNAs lipoplexes: A combinatory tools to predict the efficacy of complexation. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2013, 436, 459-466.	2.3	11
81	Qualitative and semiquantitative analysis of the protein coronas associated to different functionalized nanoparticles. Nanomedicine, 2018, 13, 407-422.	1.7	11
82	TweenÂ® Preserves Enzyme Activity and Stability in PLGA Nanoparticles. Nanomaterials, 2021, 11, 2946.	1.9	11
83	Tunneling Nanotubes: A New Target for Nanomedicine?. International Journal of Molecular Sciences, 2022, 23, 2237.	1.8	11
84	Vegetable cells in Papanicolaou-stained cervical smears. Diagnostic Cytopathology, 2006, 34, 45-49.	0.5	10
85	Novel polymeric/lipidic hybrid systems (PLHs) for effective Cidofovir delivery: Preparation, characterization and comparative in vitro study with polymeric particles and liposomes. International Journal of Pharmaceutics, 2011, 413, 220-228.	2.6	10
86	Liposome-oligonucleotides interaction for in vitro uptake by COS I and HaCaT cells. Journal of Drug Targeting, 2005, 13, 295-304.	2.1	9
87	Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma. Haematologica, 2015, 100, e467-e470.	1.7	9
88	Microfluidic Technology for the Production of Hybrid Nanomedicines. Pharmaceutics, 2021, 13, 1495.	2.0	9
89	Immunoliposomal systems targeting primary effusion lymphoma: <i>in vitro</i> study. Nanomedicine, 2010, 5, 1051-1064.	1.7	8
90	Molecular characterization of a Marekâ€™s disease virus strain detected in tumour-bearing turkeys. Avian Pathology, 2020, 49, 202-207.	0.8	8

#	Article	IF	Citations
91	Application of poly-L-lactide screws in flat foot surgery: histological and radiological aspects of bio-absorption of degradable devices. Histology and Histopathology, 2012, 27, 485-96.	0.5	8
92	Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain. CNS and Neurological Disorders - Drug Targets, 2016, 15, 1079-1091.	0.8	8
93	The loading of labelled antibody-engineered nanoparticles with Indinavir increases itsin vitroefficacy againstCryptosporidium parvum. Parasitology, 2011, 138, 1384-1391.	0.7	7
94	Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments. Pharmaceutics, 2022, 14, 1450.	2.0	7
95	Flow cytometry and live confocal analysis for the evaluation of the uptake and intracellular distribution of FITC-ODN into HaCaT cells. Journal of Liposome Research, 2009, 19, 241-251.	1.5	6
96	Functionalization of liposomes: microscopical methods for preformulative screening. Journal of Liposome Research, 2015, 25, 150-156.	1.5	6
97	In vitro treatment of congenital disorder of glycosylation type Ia using PLGA nanoparticles loaded with GDPâ€'Man. International Journal of Molecular Medicine, 2019, 44, 262-272.	1.8	4
98	Chemo-enzymatic synthesis of levodropropizine. Il Farmaco, 2003, 58, 1029-1032.	0.9	3
99	Biocatalytic Asymmetric Synthesis of (S)- and (R)-Timolol. Synthesis, 2004, 2004, 1625-1628.	1.2	2
100	Advances and Perspectives for Central Nervous System Drug Delivery: The Interface Between Nanotechnology and Neuroscience. Journal of Nanoneuroscience, 2012, 2, 1-4.	0.5	2
101	The Bridge Between Nanotechnology and Neuroscience: Neuro-Nanomedicine. Journal of Nanoneuroscience, 2012, 2, 20-26.	0.5	2
102	Nanomedicines for brain diseases: where we are and where we are going. Therapeutic Delivery, 2021, 12, 631-635.	1.2	1
103	I14â€…Translational potential of cholesterol supplementation-based strategies for huntingtonâ€™s disease. , 2018, , .		1
104	Glioblastoma: State of the Art of Treatments and Applications of Polymeric and Lipidic Nanomedicines. Neuromethods, 2021, , 1-61.	0.2	1
105	Chemo-enzymatic Synthesis of Levodropropizine.. ChemInform, 2004, 35, no.	0.1	0
106	Nanotechonology for Drug Targeting. Advances in Science and Technology, 0, , .	0.2	0
107	L16â€…Identifying a therapeutic regimen for cholesterol delivery to huntingtonâ€™s disease brain. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A95.2-A95.	0.9	0
108	Glycopeptide-Decorated Nanoparticles as Drug Carriers for CNS: Effects of Surface Coverage and Carbohydrate Type. Journal of Nanoneuroscience, 2009, 1, 152-157.	0.5	0